Patologian yksikkö

Julkaisut 2011
Publications 2011

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.

1 Aho H. Patologian laboratorio haasteiden edessä.
2 Aro K et al. Expression pattern of claudins 1 and 3-an auxiliary tool in predicting behavior of mucoepidermoid carcinoma of salivary gland origin.
3 Avoranta ST et al. Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo) radiotherapy.
4 Bello IO et al. Cancer-associated fibroblasts, a parameter of the tumor microenvironment, overcomes carcinoma-associated parameters in the prognosis of patients with mobile tongue cancer.
5 Boder JME et al. Breast cancer patients in Libya: Comparison with european and central african patients.
6 Boström P et al. MMP-1 expression has an independent prognostic value in breast cancer.
7 Buhmeida A et al. Prognostic value of mitotic counts in breast cancer of Saudi Arabian patients.
8 Böckelman C et al. Prognostic role of CIP2A expression in serous ovarian cancer.
9 Farschchian M et al. Serpin peptidase inhibitor clade a member 1 (SerpinA 1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.
10 Frantzén J et al. In vivo and in vitro study of a polylactide-fiber-reinforced beta-tricalcium phosphate composite cage in an ovine anterior cervical intercorporal fusion model.
11 Fröhlich C et al. ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression.
12 Heiska L et al. Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment.
13 Helle L et al. Traditional microscopy instruction versus process-oriented virtual microscopy instruction: a naturalistic experiment with control group.
14 Hynninen J et al. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer.
15 Khanna A et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells.
16 Kivinen K. Nuclear Matrix in Apoptotic Cell Death and Cell Proliferation.
17 Kokko L-L et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma.
18 Korkeila E. Hypoxia-Associated Biomarkers in Rectal Cancer Treated by Preoperative Radiotherapy or Chemoradiotherapy.
19 Korkeila E et al. Pronounced tumour regression after radiotherapy is associated with negative/weak glucose transporter-1 expression in rectal cancer.
20 Korkeila EA et al. Carbonic anhydrase IX, hypoxia-inducible factor-1 alfa, ezrin and glucose transporter-1 as predictors of disease outcome in rectal cancer.
21 Korkeila EA et al. Preoperative radiotherapy modulates ezrin expression and its value as a predictive marker in patients with rectal cancer.
22 Koskivuo I et al. Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma.
23 Landor SK et al. Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms.
24 Laranne J et al. Nielusyövän hoidon ajankohtaiset kysymykset.
25 Laulajainen M et al. Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor merlin1.
26 Lendorf ME et al. Syndecan-I and syndecan-4 are independent indicators in breast carcinoma.
27 Lindholm P et al. PET imaging of blood flow and glucose metabolism in localized musculoskeletal tumors of the extremities.
28 Lundbertg M et al. Increased incidence of oropharyngeal cancer and p16 expression.
29 Miao Q. Morphometric Study of Cerebral Arterioles in CADASIL.
30 Nandelstadh P von et al. Analysis of myotilin turnover provides mechanistic insight into the role of myotilinopathy-causing mutations.
31 Nygårdas M et al. Treatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5.
32 Peltola MT et al. Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(145) or Lys(146) from fPSA without internal cleavages at Lys(145) or Lys(146).
33 Peltola MT et al. Intact and internally cleaved free prostate-specific antigen in patients with prostate cancer with different pathologic stages and grades.
34 Rappu P et al. Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay.
35 Rönkkö H et al. The capacity of the distal stump of peripheral nerve to receive growing axons after two and six months denervation.
36 Silvola JM et al. Uptake of 68gallium in atherosclerotic plaques in LDLR-/- ApoB 100/100 mice.
37 Silvola JMU et al. Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques.
38 Silvola JMU et al. Detection of hypoxia by [18F]EF5 in atheroschlerosis plaques in mice .
39 Skalova A et al. Cribriform adenocarcinoma of minor salivary gland origin principally affecting the tongue: characterization of new entity.
40 Urgard E et al. Metagenes associated with survival in non-small cell lung cancer.
41 Vainio P et al. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
42 Vihinen P et al. Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report.
43 Ålgars A et al. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.
Julkaisutietokanta 23.11.2012 Publications Data Base 23.11.2012